TSX · EPRX.TO
Eupraxia Pharmaceuticals Inc.
CA$10.14-CA$0.14 (-1.36%)
Eupraxia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.48% below the high.
Loading market information…
TSXV · TLT.V · CAD
Stock price, earnings
Quote as of Oct 29, 2026, 07:58 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Theralase Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.22% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Theralase Technologies Inc.’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of -CA$0.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Theralase Technologies Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has a collaboration with the National Microbiology Laboratory, a Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. Theralase Technologies Inc. is based in Toronto, Canada.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | Mar 25, 2025 | -CA$0.000.0% vs estimate | CA$410.00K0.0% vs estimate |
|---|
| Q3 2024 | Nov 27, 2024 | -CA$0.00-48.15% vs estimate | CA$346.58K0.0% vs estimate |
|---|
| Q2 2024 | Aug 12, 2024 | -CA$0.00-48.48% vs estimate | CA$100.85K+0.05% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$10.14-CA$0.14 (-1.36%)
Eupraxia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.48% below the high.
CA$0.25+CA$0.01 (+4.17%)
BetterLife Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 45.65% below the high.
CA$0.99CA$0.00 (0.0%)
Helix BioPharma Corp.’s quoted price sits in the lower half of its reported 52-week range, 61.92% below the high.
CA$0.81-CA$0.01 (-1.22%)
Arch Biopartners Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.14% below the high.
CA$4.65-CA$0.21 (-4.32%)
BriaCell Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 74.17% below the high.
CA$0.08+CA$0.01 (+6.67%)
Resverlogix Corp.’s quoted price sits in the lower half of its reported 52-week range, 46.67% below the high.
CA$0.35CA$0.00 (0.0%)
Defence Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
CA$0.27-CA$0.01 (-3.57%)
Onco-Innovations Limited’s quoted price sits in the lower half of its reported 52-week range, 85.25% below the high.
